Integrated Regional Information Networks - September 25, 2002
In a statement issued on Wednesday, the Kenya Coalition for Access to Essential Medicines said official statements in recent weeks had created the impression that the government was ready to implement a comprehensive programme to make cheaper anti-retroviral (ARV) drugs available to Kenya's estimated 400,000 AIDS patients. However, no national procurement policy had been put in place to guide the implementation of the programme.
The importation of cheaper generic AIDS drugs into Kenya was made possible by a recent amendment to the new Industrial Property Act. However, the government is yet to develop a comprehensive policy to address the complex processes involved in the implementation of the new Act, the statement said.
"We applaud the government's willingness to make ARV's widely available to Kenyans," Liza Kimbo, a member of the coalition, stated. "But these and other similar statements by government representatives sow confusion and obscure the fact that there are still major obstacles to the implementation of a comprehensive ARV programme in Kenya. We would like to see a clear and well defined policy."
The coalition took issue with recent remarks by some senior officials in the health ministry who have promised that the government is ready to purchase ARV therapies for free use or at minimal charges. This position is, however, not true according to the coalition, which sees other major obstacles preventing the importation of ARVs into the country.
One such obstacle, the coalition argued, was the fact that the majority of ARVs had not yet been registered in Kenya. The Pharmacy and Poisons Board - the government authority which approves and registers medicines before they can be marketed for use in Kenya - was "extremely slow", the statement said.
"They act as if there is no emergency in Kenya," Jon Wasonga, another coalition member, said.
HIV/AIDS has been declared a national disaster in Kenya. Official figures indicate that 500 people in the country die daily of AIDS.
020925
IR020915
Copyright © 2002 - Integrated Regional Information Networks (IRIN). Reproduction of this article (other than one copy for personal reference) must be cleared through the Integrated Regional Information Network. .
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980 – 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .